Metolazone NDC 63629-8722

NDC codes

FDA NDC Directory

Product NDC (as listed)63629-8722Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63629-8722Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63629-8722-1	63629872201	100 TABLET in 1 BOTTLE (63629-8722-1)Marketed from Aug 19, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Metolazone
Generic name (nonproprietary): metolazone
Active ingredients: Metolazone — 2.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076732
Marketing start: Dec 19, 2003
Listing expires: Dec 31, 2026
Other FDA classes: Increased Diuresis (Physiologic effect)
Identifiers: Product ID 63629-8722_1c9bb8dd-aaa5-401f-bde3-122a543a5fd7SPL ID 1c9bb8dd-aaa5-401f-bde3-122a543a5fd7SPL set ID 88c93278-7cf6-4f84-bc03-44bfb8b91e37RxCUI 197979UNII TZ7V40X7VX
Pharmacologic class: Thiazide-like Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463629872201 followed by a unit qualifier and the quantity

Package 63629-8722-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 1, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE Metolazone is indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone is also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its s…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076732

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076732
Product	Strength	Form · route	Labeler	Product NDC
Metolazone	Metolazone 2.5 mg/1	TabletOral	Aphena Pharma Solutions - Tennessee, LLC	71610-285
Metolazone	Metolazone 2.5 mg/1	TabletOral	Sandoz Inc	0185-5050
Metolazone	Metolazone 2.5 mg/1	TabletOral	Bryant Ranch Prepack	72162-1056